Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satralizumab in anti-NMDAR or anti-LGI1 autoimmune encephalitis
2021-002395-39Phase 3Active
- Sponsor
- Roche
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in anti-NMDA receptor encephalitis and leucine-rich comparing Satralizumab with Placebo (2 arms). Primary endpoint: Proportion of participants with mRS score improvement >=1 from baseline and no use of rescue therapy at Week 24. Started Mar 2022; status: active.
02
Drugs
satralizumab
03
Conditions
anti-NMDA receptor encephalitisleucine-rich
Beyond the preview
Go deeper on 2021-002395-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002395-39.